Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:1/20/2019
Start Date:June 22, 2017
End Date:June 2024
Contact:Iovance Biotherapeutics Clinical Inquiries
Email:Clinical.Inquiries@iovance.com
Phone:650-260-7120

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive
cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145)
followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the
treatment of patients with recurrent, metastatic, or persistent cervical carcinoma

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing
process, as originally developed by the NCI, for the treatment of patients with recurrent,
metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study
involves patients receiving a NMA lymphocyte depleting preparative regimen, followed by
infusion of autologous TIL followed by the administration of a regimen of IL-2.

Inclusion Criteria:

To be eligible for the study, patients must meet ALL of the following criteria prior to
enrollment in the study:

1. Must be ≥ 18 years of age at the time of consent.

2. Must have recurrent, metastatic, or persistent squamous cell carcinoma, adenosquamous
carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment
with surgery and/or radiation therapy and for which no other therapies are expected to
have significant benefit, in the opinion of the Investigator.

3. Must have at least 1 lesion that is resectable for TIL generation. The resected TIL
generating lesion(s) should yield at least 1.5 cm in diameter post-resection of tumor
tissue. Following resection for TIL generation, must have a remaining measurable
target lesion as defined by RECIST v1.1

4. Must have had at least 1 and no more than 3 prior systemic chemotherapeutic treatments
(such as carboplatin/cisplatin, paclitaxel, and bevacizumab except where there are
contraindications) for cervical carcinoma. Patients must have progressive disease
while receiving or after the completion of the most recent prior treatment.

5. Any prior therapy directed at the malignant tumor must be discontinued at least 28
days prior to tumor resection. Radiation therapy may have been received up to 28 days
prior to tumor resection for lesions not expected to be used for TIL generation or
target lesions.

6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

7. Patients must be seronegative for the human immunodeficiency virus (HIV). Patients
with positive serology for hepatitis B virus surface antigen (HBsAg), hepatitis B core
antibody (anti-HBc), or hepatitis C virus (anti-HCV) indicating acute or chronic
infection may be enrolled if the viral load by polymerase chain reaction (PCR) is
undetectable with/without active treatment.

8. Patients of childbearing potential must be willing to practice an approved method of
birth control starting at the time of informed consent and for 1 year after the
completion of the study treatment regimen.

Exclusion Criteria:

1. Patients who have received an organ allograft or prior cell transfer therapy except
for prior LN-145 therapy.

2. Patients who are on a systemic steroid therapy > 10 mg of prednisone daily or other
steroid equivalent.

3. Patients who currently have prior therapy-related toxicities greater than Grade 1
according to NCI-CTCAE v4.03; except for peripheral neuropathy, alopecia, or vitiligo
prior to enrollment/resection.

4. Patients who have a contraindication to or history of hypersensitivity reaction to any
component or excipients of the TIL therapy and the other study drugs.

5. Patients with active systemic infections, coagulation disorders or other active major
medical illnesses of the cardiovascular, respiratory, or immune system.

6. Patients with symptomatic and/or untreated brain metastases (of any size and any
number).

7. Patients who have any form of primary or acquired immunodeficiency syndrome, such as
severe combined immunodeficiency disease or acquired immune deficiency syndrome
(AIDS).

8. Patients who have a diagnosis of end-stage renal disorder requiring hemodialysis.

9. Patients who have a left ventricular ejection fraction (LVEF) < 45% or who are New
York Heart Association (NYHA) Class 2 or higher.

10. Patients who have a forced expiratory volume in 1 second (FEV1) of less than or equal
to 60% of predicted normal.

11. Patients who have received a live or attenuated vaccine within 28 days of the NMA-LD
regimen.

12. Patients whose cancer requires immediate treatment or who would otherwise suffer a
disadvantage by participating in this study.

13. Patients who have received prior treatment with immunotherapy (eg, anti-PD-1
anti-PD-L1, or anti-CTLA4 antibodies)
We found this trial at
20
sites
Pittsburgh, Pennsylvania 15232
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Baltimore, Maryland 21231
410-955-6190
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Los Angeles, California 90033
213) 740-2311
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Augusta, Georgia 30912
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
529 S Jackson St
Louisville, Kentucky 40202
(502) 562-4369
James Graham Brown Cancer Center No one should feel compelled to leave Kentucky to seek...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
New Orleans, Louisiana 70112
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
185 University Avenue
Newark, New Jersey 07103
?
mi
from
Newark, NJ
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pierre Bénite, Rhone-alpes 69495
?
mi
from
Pierre Bénite,
Click here to add this to my saved trials
San Diego, California 92093
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials